Management of castration‐resistant prostate cancer: a call to urologists

This publication has 23 references indexed in Scilit:

• 31 Evaluating the antitumour activity of docetaxel following treatment with abiraterone acetate and steroids: Evidence for cross-resistance
  Critical Reviews in Oncology/Hematology, 2011
• EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
  European Urology, 2011
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
  The Lancet, 2010
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
  The Lancet, 2010
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
  The Lancet, 2009
• Docetaxel down‐regulates the expression of androgen receptor and prostate‐specific antigen but not prostate‐specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy
  The Prostate, 2009
• Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  Annals of Oncology, 2009
• Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
  New England Journal of Medicine, 2004
• Microtubules as a target for anticancer drugs
  Nature Reviews Cancer, 2004
• Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
  New England Journal of Medicine, 1998